Stoke Therapeutics (STOK) Shares Outstanding (2018 - 2026)

Stoke Therapeutics has reported Shares Outstanding for 9 years, with the latest figure at $62.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 14.0% year-over-year to $62.2 million; the trailing twelve-month figure through Mar 2026 stood at $62.2 million (up 14.0% YoY), and the FY2025 full-year result was $58.9 million, up 9.05% from the prior year.
• Shares Outstanding for Q1 2026 stood at $62.2 million, up from $58.9 million in the prior quarter.
• The five-year high for Shares Outstanding was $62.2 million in Q1 2026, with the low at $39.0 million in Q1 2022.
• Average Shares Outstanding over 5 years is $48.7 million, with a median of $46.5 million recorded in 2024.
• Year-over-year, Shares Outstanding rose 19.52% in 2024 and rose 4.12% in 2025.
• Tracing STOK's Shares Outstanding over 5 years: stood at $39.4 million in 2022, then gained by 16.43% to $45.9 million in 2023, then advanced by 17.67% to $54.0 million in 2024, then grew by 9.05% to $58.9 million in 2025, then increased by 5.63% to $62.2 million in 2026.
• The last three Shares Outstanding figures came in at $62.2 million (Q1 2026), $58.9 million (Q4 2025), and $55.1 million (Q3 2025), per Business Quant data.

Peer Comparison